SCOUT Shows Challenges Of Cardiovascular Outcomes Trials In Obesity
Abbott’s SCOUT study of Meridia’s cardiovascular safety shows the design, enrollment and interpretation challenges facing obesity drug developers if FDA were to require CV outcomes studies either pre- or post-approval.
You may also be interested in...
The major lesson of FDA’s serial rejection of three obesity drugs in a six-month span is that safety is paramount in the weight loss space. That’s agreed. But beyond that, it’s tough to know what to expect, and obesity drug developers face an uncertain regulatory path going forward.
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.